To enhance the diagnosis of unclassifiable, non-CLL B-LPDs using next-generation sequencing technology.
Description: This will be reported as a percentage of the total number of cases sequencedMeasure: Proportion of cases where a definite category and/or detectable mutation can be identified. Time: 2 years
Description: Age and sex distribution will be reported along with the proportion of cases in each immunomorphologic categoryMeasure: Demographics and distribution in each immunomorphological category Time: 2 years
Description: The distribution of mutations within each immunomorphological category will be reported descriptively.Measure: Correlation of each immunomorphological category with the mutation profile. Time: 2 years
There is one SNP
While some of these mutations, such as the BRAF V600E mutation in Hairy Cell Leukaemia (HCL)2, are now accepted as disease defining mutations, others such as MYD88 and NOTCH1/2 mutations are found in more than one subtype of B-LPD3. --- V600E ---